Tesetaxel - Odonate Therapeutics

Drug Profile

Tesetaxel - Odonate Therapeutics

Alternative Names: DJ-927

Latest Information Update: 22 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Pharmaceutical
  • Developer Genta (CEASED); Odonate Therapeutics
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Discontinued Bladder cancer; Colorectal cancer; Gastric cancer; Malignant melanoma; Prostate cancer; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 02 Jun 2018 Efficacy and safety data from a phase II trial in Breast cancer released by Odonate Therapeutics
  • 01 Dec 2017 Phase-III clinical trials in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03326674)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top